|
Population size |
108
|
|
Reproduction number (WT) |
2.5 |
|
Recovery rate |
1/14 days-1
|
|
Transmission rate |
|
|
Cross-reactivity between WT and variant |
1 or 0.6 |
|
Maximum vaccine efficacy |
0.95 |
|
Antigenic mismatch between vaccine and WT |
0 |
|
Antigenic mismatch between vaccine and variant |
|
|
Eligibility of infected individuals for vaccination; 1 = eligible, 0 = ineligible |
1 |
|
Eligibility of recovered individuals for vaccination; 1 = eligible, 0 = ineligible |
1 |
|
Increase in transmissibility of variant relative to WT |
0 or 0.6 |
|
Time of variant introduction |
9 months |
|
Start of vaccine rollout |
Varies |
|
Daily per-capita vaccination rate |
Varies |
|
Final vaccination coverage |
100% |
|
Reduction in transmission due to nonpharmaceutical interventions |
0.4 |